- Home
- PCRX vs EYPT Comparison
PCRX vs EYPT Comparison
Compare PCRX & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- EYPT
- Stock Information
- Founded
- PCRX 2006
- EYPT 1987
- Country
- PCRX United States
- EYPT United States
- Employees
- PCRX N/A
- EYPT N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- PCRX Health Care
- EYPT Industrials
- Exchange
- PCRX Nasdaq
- EYPT Nasdaq
- Market Cap
- PCRX 604.7M
- EYPT 594.5M
- IPO Year
- PCRX 2011
- EYPT 2005
- Fundamental
- Price
- PCRX $24.52
- EYPT $8.53
- Analyst Decision
- PCRX Buy
- EYPT Strong Buy
- Analyst Count
- PCRX 10
- EYPT 8
- Target Price
- PCRX $27.60
- EYPT $25.71
- AVG Volume (30 Days)
- PCRX 687.3K
- EYPT 711.5K
- Earning Date
- PCRX 02-27-2025
- EYPT 03-06-2025
- Dividend Yield
- PCRX N/A
- EYPT N/A
- EPS Growth
- PCRX N/A
- EYPT N/A
- EPS
- PCRX N/A
- EYPT N/A
- Revenue
- PCRX $694,957,000.00
- EYPT $45,713,000.00
- Revenue This Year
- PCRX $4.83
- EYPT N/A
- Revenue Next Year
- PCRX $2.16
- EYPT N/A
- P/E Ratio
- PCRX N/A
- EYPT N/A
- Revenue Growth
- PCRX 4.40
- EYPT 7.50
- 52 Week Low
- PCRX $11.16
- EYPT $6.90
- 52 Week High
- PCRX $34.01
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- PCRX 76.79
- EYPT 53.88
- Support Level
- PCRX $18.18
- EYPT $7.15
- Resistance Level
- PCRX $22.36
- EYPT $9.08
- Average True Range (ATR)
- PCRX 1.28
- EYPT 0.68
- MACD
- PCRX 0.39
- EYPT 0.13
- Stochastic Oscillator
- PCRX 89.19
- EYPT 58.72
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.